Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Religious Belief at the Level of the Brain: Neural Correlates and Influence of Culture.

Gaw AC.

J Nerv Ment Dis. 2019 Jul;207(7):604-610. doi: 10.1097/NMD.0000000000001016.

PMID:
31259793
2.

Is there a role for the adverse outcome pathway framework to support radiation protection?

Chauhan V, Said Z, Daka J, Sadi B, Bijlani D, Marchetti F, Beaton D, Gaw A, Li C, Burtt J, Leblanc J, Desrosiers M, Stuart M, Brossard M, Vuong NQ, Wilkins R, Qutob S, McNamee J, Wang Y, Yauk C.

Int J Radiat Biol. 2019 Feb;95(2):225-232. doi: 10.1080/09553002.2019.1532617. Epub 2018 Oct 29.

PMID:
30373433
3.

Influence of Ethnicity on Parental Preference for Pediatric Dental Behavioral Management Techniques.

Chang CT, Badger GR, Acharya B, Gaw AF, Barratt MS, Chiquet BT.

Pediatr Dent. 2018 Jul 15;40(4):265-272.

PMID:
30345965
4.

Comparison of phase 2 cardiac rehabilitation outcomes between patients after transcatheter versus surgical aortic valve replacement.

Imran HM, Baig M, Mujib M, Beale C, Gaw A, Stabile L, Shah NR, Gordon PC, Wu WC.

Eur J Prev Cardiol. 2018 Oct;25(15):1577-1584. doi: 10.1177/2047487318792099. Epub 2018 Aug 8.

PMID:
30086685
5.

Precision medicine and improving future health care to an ageing population.

Gaw A.

Perspect Public Health. 2016 Mar;136(2):77-8. doi: 10.1177/1757913915626874. No abstract available.

PMID:
26933076
6.

'The principles of a future pharmacology': Johann Christian Reil (1759-1813) and his role in the development of clinical pharmacology.

Gaw A.

Eur J Clin Pharmacol. 2016 Jan;72(1):13-7. doi: 10.1007/s00228-015-1964-2. Epub 2015 Oct 9.

PMID:
26453462
7.

Clinical research benefits go viral via Twitter.

Gibbs CL, Greaves A, Keeling M, Gaw A, O'Neill F.

Nurs Times. 2015 May 6-12;111(19):16-7. No abstract available.

PMID:
26182599
8.

Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.

Nicholls DJ, Wiley K, Dainty I, MacIntosh F, Phillips C, Gaw A, Mårdh CK.

J Pharmacol Exp Ther. 2015 May;353(2):340-50. doi: 10.1124/jpet.114.221358. Epub 2015 Mar 3.

PMID:
25736418
9.

Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.

Austin RP, Bennion C, Bonnert RV, Cheema L, Cook AR, Cox RJ, Ebden MR, Gaw A, Grime K, Meghani P, Nicholls D, Phillips C, Smith N, Steele J, Stonehouse JP.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1616-20. doi: 10.1016/j.bmcl.2015.01.067. Epub 2015 Feb 3.

PMID:
25708618
10.

Ethics in research: practice and respect.

Gaw A, O'Neill F.

Nurs Times. 2014 May 14-20;110(20):12-3.

PMID:
24915669
11.

Reality and revisionism: new evidence for Andrew C Ivy's claim to authorship of the Nuremberg Code.

Gaw A.

J R Soc Med. 2014 Apr;107(4):138-43. doi: 10.1177/0141076814523948. Epub 2014 Feb 24. No abstract available.

12.

Are routinely collected NHS administrative records suitable for endpoint identification in clinical trials? Evidence from the West of Scotland Coronary Prevention Study.

Barry SJ, Dinnett E, Kean S, Gaw A, Ford I.

PLoS One. 2013 Sep 13;8(9):e75379. doi: 10.1371/journal.pone.0075379. eCollection 2013.

13.

Implementing a centralised pharmacovigilance service in a non-commercial setting in the United Kingdom.

Dinnett EM, Kean S, Tolmie EP, Ronald ES, Gaw A.

Trials. 2013 Jun 12;14:171. doi: 10.1186/1745-6215-14-171. Review.

14.

The COPD Biomarker Qualification Consortium (CBQC).

Casaburi R, Celli B, Crapo J, Criner G, Croxton T, Gaw A, Jones P, Kline-Leidy N, Lomas DA, Merrill D, Polkey M, Rennard S, Sciurba F, Tal-Singer R, Stockley R, Turino G, Vestbo J, Walsh J.

COPD. 2013 Jun;10(3):367-77. doi: 10.3109/15412555.2012.752807.

PMID:
23713597
15.

When death is imminent - documenting end-of-life decisions.

Gaw A, Doherty S, Hungerford P, May J.

Aust Fam Physician. 2012 Aug;41(8):614-7.

PMID:
23145405
16.

Lipid metabolism.

Young IS, Gaw A.

Curr Opin Lipidol. 2012 Oct;23(5):503-4. doi: 10.1097/MOL.0b013e328358247d. No abstract available.

PMID:
22964997
17.

Unraveling the Enigma of Bangungut: Is Sudden Unexplained Nocturnal Death Syndrome (SUNDS) in the Philippines a Disease Allelic to the Brugada Syndrome?

Gaw AC, Lee B, Gervacio-Domingo G, Antzelevitch C, Divinagracia R, Jocano F Jr.

Philipp J Intern Med. 2011 Jul;49(3):165-176.

18.

Finding maurice pappworth.

Gaw A.

Niger Med J. 2011 Oct;52(4):278. doi: 10.4103/0300-1652.93804. No abstract available.

19.

Exposing unethical human research: the transatlantic correspondence of Beecher and Pappworth.

Gaw A.

Ann Intern Med. 2012 Jan 17;156(2):150-5. doi: 10.7326/0003-4819-156-2-201201170-00012.

PMID:
22250147
20.

Searching for Pappworth.

Gaw A.

S Afr Med J. 2011 Sep 5;101(9):608. No abstract available.

PMID:
21920170
21.

Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study.

Gupta M, Martineau P, Tran T, Després JP, Gaw A, de Teresa E, Farsang C, Gensini GF, Leiter LA, Blanco-Colio LM, Egido J, Langer A; ACTFAST investigators.

J Clin Pharmacol. 2012 Jun;52(6):850-8. doi: 10.1177/0091270011407196. Epub 2011 May 24.

PMID:
21610204
22.

Clinical Trials: Minimising source data queries to streamline endpoint adjudication in a large multi-national trial.

Tolmie EP, Dinnett EM, Ronald ES, Gaw A; AURORA Clinical Endpoints Committee.

Trials. 2011 May 6;12:112. doi: 10.1186/1745-6215-12-112.

23.

Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).

Freeman DJ, Robertson M, Brown EA, Rumley A, Tobias ES, Frölich M, Slagboom PE, Jukema JW, de Craen AJ, Sattar N, Ford I, Gaw A, Greer IA, Lowe GD, Stott DJ.

BMC Geriatr. 2011 Feb 22;11:8. doi: 10.1186/1471-2318-11-8.

24.

Hikikomori, a Japanese culture-bound syndrome of social withdrawal?: A proposal for DSM-5.

Teo AR, Gaw AC.

J Nerv Ment Dis. 2010 Jun;198(6):444-9. doi: 10.1097/NMD.0b013e3181e086b1. Review.

25.

Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).

Caslake MJ, Packard CJ, Robertson M, Cooney J, Nelson JJ, Ford I, Gaw A, Jukema JW, Macfarlane PW, Stott DJ, Shepherd J; PROSPER Study Group.

Atherosclerosis. 2010 May;210(1):28-34. doi: 10.1016/j.atherosclerosis.2009.10.041. Epub 2009 Nov 10.

PMID:
20005516
26.

Dynamic regulation of the endocannabinoid system: implications for analgesia.

Sagar DR, Gaw AG, Okine BN, Woodhams SG, Wong A, Kendall DA, Chapman V.

Mol Pain. 2009 Oct 8;5:59. doi: 10.1186/1744-8069-5-59. Review.

27.

Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.

Gensini GF, Gori AM, Dilaghi B, Rostagno C, Gaw A, Blanco-Colio LM, de Teresa E, Egido J, Farsang C, Leiter LA, Martineau P, Nozza A, Langer A; Achieve Cholesterol Targets Fast withAtorvastatin Stratified Titration Investigators.

Int J Cardiol. 2010 Jul 23;142(3):257-64. doi: 10.1016/j.ijcard.2008.12.213. Epub 2009 Feb 12.

PMID:
19217176
28.

Accuracy of patient recall of preoperative symptom severity (angina and breathlessness) at one year following aorta-coronary artery bypass grafting.

Lindsay GM, Niven KA, Brodie EE, Gaw A, Belcher PR.

J Clin Nurs. 2009 Feb;18(3):418-25. doi: 10.1111/j.1365-2702.2008.02559.x.

PMID:
19191989
29.

Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.

Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Egido J; ACTFAST investigators.

Kidney Int Suppl. 2008 Dec;(111):S60-3. doi: 10.1038/ki.2008.514.

30.

How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.

Leiter LA, Martineau P, de Teresa E, Farsang C, Gaw A, Gensini G, Langer A; ACTFAST 1 & 2 investigators.

J Fam Pract. 2008 Oct;57(10):661-8.

PMID:
18842192
31.

Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2.

Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, Gaw A, Meghani P, Shelton P, Wright TJ, Mallinder PR.

Mol Pharmacol. 2008 Nov;74(5):1193-202. doi: 10.1124/mol.107.044610. Epub 2008 Aug 1.

PMID:
18676678
32.

Should we be targeting triglyceride as well as LDL cholesterol in the battle against coronary heart disease?

Gaw A.

Nat Clin Pract Cardiovasc Med. 2008 Aug;5(8):438-9. doi: 10.1038/ncpcardio1249. Epub 2008 Jun 10. No abstract available.

PMID:
18542105
33.

Lymphotoxin-alpha C804A polymorphism is a risk factor for stroke. The PROSPER study.

Trompet S, de Craen AJ, Slagboom P, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Ford I, Gaw A, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Jukema JW; PROSPER Group.

Exp Gerontol. 2008 Aug;43(8):801-5. doi: 10.1016/j.exger.2008.04.006. Epub 2008 Apr 22.

PMID:
18504081
34.

Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.

Blanco-Colio LM, Martín-Ventura JL, Gómez-Guerrero C, Masramon X, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Egido J.

Eur J Pharmacol. 2008 May 31;586(1-3):259-65. doi: 10.1016/j.ejphar.2008.02.042. Epub 2008 Feb 26.

PMID:
18374327
35.

Genetic variation in the interleukin-1 beta-converting enzyme associates with cognitive function. The PROSPER study.

Trompet S, de Craen AJ, Slagboom P, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Ford I, Gaw A, Macfarlane PW, Packard CJ, Stott DJ, Jukema JW, Westendorp RG; PROSPER Group.

Brain. 2008 Apr;131(Pt 4):1069-77. doi: 10.1093/brain/awn023. Epub 2008 Feb 26.

PMID:
18304957
36.

Association between apolipoprotein E4 and cognitive decline in elderly adults.

Packard CJ, Westendorp RG, Stott DJ, Caslake MJ, Murray HM, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Jolles J, Perry IJ, Sweeney BJ, Twomey C; Prospective Study of Pravastatin in the Elderly at Risk Group.

J Am Geriatr Soc. 2007 Nov;55(11):1777-85.

PMID:
17979899
38.

Mental health care of Filipino Americans.

Sanchez F, Gaw A.

Psychiatr Serv. 2007 Jun;58(6):810-5.

PMID:
17535941
39.

Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events: the PROSPER study.

Trompet S, Pons D, DE Craen AJ, Slagboom P, Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, Ford I, Hyland M, Gaw A, Macfarlane PW, Packard CJ, Norrie J, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Jukema JW.

Ann N Y Acad Sci. 2007 Apr;1100:189-98.

PMID:
17460178
40.

Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.

Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Egido J; ACTFAST investigators.

Am Heart J. 2007 May;153(5):881-8.

PMID:
17452168
42.

A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.

Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM.

J Clin Oncol. 2007 Feb 20;25(6):634-41.

PMID:
17308268
43.

C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).

Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Murphy MB, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Shepherd J; PROSPER Study Group.

Circulation. 2007 Feb 27;115(8):981-9. Epub 2007 Feb 5.

PMID:
17283264
44.

Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.

Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Hérnandez G, Egido J; ACTFAST investigators.

Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):168-74. Epub 2006 Oct 19.

45.

Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.

Martineau P, Gaw A, de Teresa E, Farsang C, Gensini GF, Leiter LA, Langer A; ACTFAST investigators.

Atherosclerosis. 2007 Mar;191(1):135-46. Epub 2006 Apr 27.

PMID:
16643923
46.

Beyond consent: the potential for atrocity.

Gaw A.

J R Soc Med. 2006 Apr;99(4):175-7. Review. No abstract available.

47.

Offering results to research participants.

Dinnett EM, Mungall MM, Gordon C, Ronald ES, Gaw A.

BMJ. 2006 Mar 4;332(7540):549-50. No abstract available.

48.

Identification of mitogen-activated protein kinase signaling pathways that confer resistance to endoplasmic reticulum stress in Saccharomyces cerevisiae.

Chen Y, Feldman DE, Deng C, Brown JA, De Giacomo AF, Gaw AF, Shi G, Le QT, Brown JM, Koong AC.

Mol Cancer Res. 2005 Dec;3(12):669-77.

49.

Closing out a large clinical trial: lessons from the prospective study of pravastatin in the elderly at risk (PROSPER).

Dinnett EM, Mungall MM, Kent JA, Ronald ES, Gaw A; PROSPER Study Group.

Clin Trials. 2004;1(6):545-52.

PMID:
16279295
50.

Unblinding of trial participants to their treatment allocation: lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).

Dinnett EM, Mungall MM, Kent JA, Ronald ES, McIntyre KE, Anderson E, Gaw A; PROSPER Study Group.

Clin Trials. 2005;2(3):254-9.

PMID:
16279148

Supplemental Content

Support Center